Last updated: February 15, 2026
Overview:
NDC 69367-0268 is a medication marketed under the brand name Ocrevus (ocrelizumab). It is an anti-CD20 monoclonal antibody approved by the FDA for multiple sclerosis (MS) treatment, including relapsing forms (RMS) and primary progressive multiple sclerosis (PPMS). It has received significant market penetration since its approval in 2017 for RMS and later in 2019 for PPMS. The drug’s market and pricing trends are driven by MS prevalence, reimbursement policies, competition, and manufacturing costs.
Market Size and Dynamics
Prevalence of Multiple Sclerosis:
- U.S. estimates: Approx. 900,000 cases, with 70% classified as relapsing-remitting MS (RRMS) and 10% as primary progressive MS (PPMS) (National Multiple Sclerosis Society, 2022).
- Global estimates: Approximately 2.8 million cases, with developed markets accounting for the largest share.
Market Share and Penetration:
- Ocrevus captured approximately 24% of the MS biologics market in the U.S. during 2022, following its introduction, competing primarily with drugs like rituximab, natalizumab, and alemtuzumab.
- The drug’s administration mode (IV infusion every six months) influences patient and provider preferences compared to oral agents like fingolimod.
Pricing Benchmarks:
- Initial U.S. list price: $65,000 per infusion (every six months).
- Total annual costs: Approximately $130,000, considering two infusions per year.
- Reimbursement adjustments, discounts, and patient assistance programs modify net payer costs.
Price Projection Methodology
The pricing trajectory of Ocrevus over the next five years considers factors such as market penetration, competition, cost inflation, and policy changes.
Assumptions:
- Market share will reach approximately 30–35% of the MS biologics segment within three to five years.
- The list price for infusions is expected to increase at an annual rate of 3%, consistent with drug inflation trends.
- Competitive pressure from biosimilars and newer agents may limit price growth, especially beyond 2025.
- Payer negotiations and discounts could reduce the net price by 15–25%.
Price Forecast:
| Year |
Estimated List Price per Infusion |
Total Annual Cost (Two infusions) |
Note |
| 2023 |
$66,950 |
$133,900 |
3% inflation; current pricing |
| 2024 |
$68,960 |
$137,920 |
Price increase assumption |
| 2025 |
$70,985 |
$141,970 |
Potential stabilization due to biosimilars |
| 2026 |
$73,055 |
$146,100 |
Market saturation influences |
| 2027 |
$75,146 |
$150,292 |
Biosimilar entry begins affecting pricing |
Note: These projections assume no drastic policy-driven reductions or reimbursement reforms.
Market Trends Affecting Pricing
-
Biosimilar Competition:
Similar biologics entering the market could decrease prices by 20–30% over time, especially beyond 2025. For example, biosimilar rituximab, which has a lower manufacturing cost, can undercut Ocrevus pricing in certain markets.
-
Regulatory and Policy Factors:
Legislative measures aimed at reducing drug prices could moderate inflation or lead to price caps, particularly in government-funded programs like Medicare and Medicaid.
-
Development of Oral and Subcutaneous Alternatives:
New formulations and oral therapies (e.g., fingolimod, ozanimod) could alter market share dynamics, pressuring Ocrevus to justify premium pricing.
-
Market Penetration and Reimbursement Trends:
Increasing adoption may sustain higher prices. However, payer pushback and contract negotiations aim to reduce costs, affecting actual net prices.
Revenue and Price Sensitivity
Considering current market share and the price projections, Ocrevus’s total revenue from U.S. sales could range between $1.8 billion and $2.3 billion annually by 2027, assuming continued growth. Price sensitivity analyses highlight that a 10% reduction in net price can significantly impact revenues, emphasizing the importance of payer negotiations and cost controls.
Competitive Landscape
| Competitors |
Key Attributes |
Market Share (2022) |
Notable Features |
| Rituximab (biosimilars in development) |
Lower-cost biosimilars, off-label use for MS |
~15% (estimated) |
Cost advantage, off-label prescribing hurdles |
| Natalizumab (Tysabri) |
High efficacy, infusion every four weeks |
7% |
Risk of PML, frequent dosing |
| Alemtuzumab (Lemtrada) |
High efficacy, notable adverse events |
3% |
Limited patient pool, monitoring requirements |
The entry of biosimilars may accelerate price erosion and affect Ocrevus’s market share over 2025–2027.
Key Takeaways
- Ocrevus holds a significant position in the MS biologics market with stable revenue potential, provided it sustains market share through effective pricing and clinical differentiation.
- Price increases are expected to slow from their historical levels due to biosimilar competition, regulatory pressures, and payer pushback.
- The list price is projected to rise modestly at about 3% annually, with net prices possibly declining due to discounts.
- The entry of biosimilars and alternative therapies will influence pricing trends and market share dynamics over the next five years.
- Market penetration strategies and payer negotiations play a crucial role in shaping the drug’s financial outlook.
FAQs
1. Will the price of Ocrevus decrease due to biosimilar competition?
Yes, biosimilar entrants are likely to reduce effective prices by 20–30% starting around 2025, impacting revenue and market share.
2. What factors could influence Ocrevus’s future price beyond inflation?
Regulatory reforms, policy-driven price caps, and healthcare system reforms targeting drug costs can exert downward pressure.
3. How does Ocrevus's dosing schedule affect its pricing strategy?
Infusions every six months allow for predictable revenue streams but may also increase market durability by reducing patient switching. It influences pricing negotiations favorably compared to more frequent dosing regimens.
4. Could new market entrants render Ocrevus obsolete?
Potentially. Advances in oral MS therapies or experimental treatments could diminish Ocrevus’s market share, forcing price adjustments.
5. How does Ocrevus's pricing compare internationally?
Prices vary significantly; high-income countries often pay more, while countries with price controls or single-payer systems secure lower prices.
References
[1] National Multiple Sclerosis Society. "MS Prevalence Data." 2022.
[2] IQVIA. "U.S. MS Biologics Market Share Report," 2022.
[3] FDA. "Ocrevus (ocrelizumab) Approval Documents," 2017, 2019.
[4] EvaluatePharma. "Drug Price and Revenue Data," 2023.
